Earnings call transcript: Teraplast’s Q1 2026 results show revenue decline amid challenges

Teraplast reported Q1 2026 revenue of RON 236 million, down 6% year over year, with EBITDA falling 58% to RON 8.9 million and a net loss of RON 10.6 million versus a RON 1.2 million profit last year. Results were pressured by severe winter weather, Hungary election-related project delays, and Middle East conflict-driven raw material volatility, partially offset by gross margin expansion to 40% and improved packaging performance. Management expects recovery from Q3 onward as Hungarian EU-funded infrastructure spending and operational improvements begin to support results.

Analysis

TRP is a classic “bad quarter, better setup” name: the first-order hit is visible in earnings, but the second-order question is whether the mix shift and margin discipline are enough to make the next two quarters meaningfully better. The key signal is that gross margin held up despite lower volumes, which usually means pricing power and/or input-cost pass-through are starting to outrun top-line weakness; if that persists, EBITDA should recover faster than revenue. The market is likely still pricing the stock off the last reported loss rather than the forward operating leverage that can emerge once infrastructure spending normalizes.

The bigger macro lever is Hungary and FX. If EU-funded public works restart in Q3, TRP gets a delayed but potentially sharp re-acceleration in the highest-beta part of its demand mix, while currency depreciation can partially offset domestic weakness for export sales; that combination creates a more favorable hedge than the headline loss suggests. The risk is timing: if public projects slip another quarter, leverage can look elevated longer than management expects, and the market may punish the stock for balance-sheet optics before the operating recovery shows up.

The contrarian angle is that the current setup may be less about absolute fundamentals and more about expectations reset. The stock already trades near the low end of its range, so the marginal downside from another merely “okay” quarter is likely smaller than the upside from even modest sequential improvement in packaging, windows restructuring, or subsidy cash-in. What the market may be missing is that these businesses are operationally geared to volume recovery, so the earnings rebound could be nonlinear once raw-material volatility settles and working capital stops expanding.

Key Decisions for Investors

• Long TRP on weakness into Q2 results: build 1/2 position only if the stock trades near the 52-week low zone, targeting a 15-25% rebound if Q2 confirms sequential EBITDA recovery; cut if leverage rises again without revenue stabilization.
• Pair trade: long TRP / short a regional industrials basket with more exposed domestic demand and less FX benefit, for a 1-3 month horizon; thesis is that TRP’s export mix and operating leverage give it a cleaner inflection trade.
• Use a tight-risk call spread in TRP for the Q3 inflection window: buy 3-6 month calls financed with higher strike sales to express recovery optionality without taking full balance-sheet risk.
• Avoid adding on the basis of consensus ‘budget relief’ alone; wait for evidence that public investment has actually restarted, because the real catalyst is order visibility, not commentary.
• If EUR/RON weakness accelerates further, consider TRP as a relative beneficiary versus purely domestic Romanian names, since translation and export competitiveness can partially offset local macro drag.